Ursodesoxycholic acid

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

UDCA; Urso

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Ursodesoxycholic acid is a water-soluble, non-toxic, natural bile acid that is formed especially in polar bears (ursus = lat. the bear). It is used as a well-tolerated drug for dissolving small gallstones and for the treatment of a number of liver diseases. Ursodesoxycholic acid is subject to an enterohepatic cycle, i.e. it is excreted through the liver into the bile and reabsorbed through the small intestine.

Half-lifeThis section has been translated automatically.

The biological half-life is about 3-6 days.

Field of application/useThis section has been translated automatically.

  • In dermatology it is successfully used for the treatment of pruritus gravidarum ( off-label use).
  • Other indications include the therapy of gallstones, biliary reflux gastritis and the symptomatic treatment of primary biliary cirrhosis. Furthermore:
  • non-obstructive cholestatic diseases, especially PBC and PSC

  • Drug-induced liver damage

  • Hepatitides

  • Studies suggest that altering the bile composition with UDCA also leads to a reduction in the rate of colon cancer in patients with ulcerative colitis.

Pregnancy/nursing periodThis section has been translated automatically.

  • Taking it in the first trimester of pregnancy is not indicated because there is not enough experience.
  • During the lactation period, intake is not recommended due to lack of data.
  • Off-label use in the therapy of pruritus gravidarum.

Dosage and method of useThis section has been translated automatically.

Treatment of Pruritus gravidarum: 15 mg/kg bw/day p.o.

Undesirable effectsThis section has been translated automatically.

Apart from mild diarrhoea, no undesirable effects are known in the treatment of Pruritus gravidarum.

InteractionsThis section has been translated automatically.

  • Decreased enteral resorption of the ursodeoxycholic acid when taken simultaneously with colestyramine, colestipol or aluminium hydroxide and/or alumina-containing antacids.
  • Increased absorption of ciclosporin by ursodeoxycholic acid.
  • Decreased absorption of ciprofloxacin by ursodeoxycholic acid.
  • Decreased plasma peak concentration of the calcium antagonist nitrendipine.
  • Induction of cytochrome P450 enzymes by ursodeoxycholic acid possible.

PreparationsThis section has been translated automatically.

Ursochol, Lithofalk

LiteratureThis section has been translated automatically.

  1. Leuschner U et al (2005) Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis. Z Gastroenterol 43: 1051-1059

Authors

Last updated on: 29.10.2020